-
公开(公告)号：US09563355B2
公开(公告)日：2017-02-07
申请号：US14254897
申请日：2014-04-17
Applicant: Rajeev Jain , Sahil Jain , Sagar Jain , Sumit Jain
Inventor： Rajeev Jain , Sahil Jain , Sagar Jain , Sumit Jain
IPC: G06F3/048 , G06F3/0488 , G06F3/01 , G06F3/023 , G06F3/0482
CPC classification number: G06F3/04886 , G06F3/018 , G06F3/0233 , G06F3/0482
Abstract: A novel keyboard interface and input method are described. The interface is driven by a dynamic, general-purpose typing and data-entry software application, with a reduced number of keys to minimize screen real-estate requirements, especially for mobile devices. At any given time, the interface presents base characters with built-in key points on or around the base characters that can be selected and/or swiped to generate characters. The key points are strategically placed based on the intuitiveness of such placements, reducing the curve for learning how to use the interface. Its advantage over other methods of input such as handwriting, voice and gesture recognition is that it is less prone to error and privacy issues. The interface occupies a dramatically smaller area of the screen compared to traditional on-screen keyboards and can provide alternate placement as well as transparency to reveal text or images underneath. It can be implemented in most mobile and other computing platforms with reduced resource requirements.
Abstract translation: 描述了一种新颖的键盘接口和输入方法。 该接口由动态的通用打字和数据输入软件应用程序驱动，具有减少的密钥数量以最小化屏幕不动产要求，特别是对于移动设备。 在任何给定的时间，界面提供基本字符，其基本字符上或周围的内置键点可以选择和/或滑动以生成字符。 基于这种展示的直观性，战略性地放置关键点，减少学习如何使用界面的曲线。 它比其他输入方法（如手写，语音和手势识别）的优点在于它不太容易出现错误和隐私问题。 与传统的屏幕键盘相比，该界面占据了显着更小的屏幕面积，并且可以提供替代放置以及透明度以显示下方的文字或图像。 它可以在大多数移动和其他计算平台上实现，资源需求减少。
-
公开(公告)号：US07931917B2
公开(公告)日：2011-04-26
申请号：US11802567
申请日：2007-05-23
Applicant: Tuula Ryde , Evan E. Gustow , Stephen B. Ruddy , Rajeev Jain , Rakesh Patel , Michael John Wilkins
Inventor： Tuula Ryde , Evan E. Gustow , Stephen B. Ruddy , Rajeev Jain , Rakesh Patel , Michael John Wilkins
IPC: A61K9/14 , A61K31/216
CPC classification number: A61K31/19 , A61K9/145 , A61K9/146 , A61K9/2077 , A61K31/14 , A61K31/216 , A61K45/06 , Y10T428/29 , A61K2300/00
Abstract: The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.
Abstract translation: 本发明涉及具有改善的药代动力学特征和降低的进食/禁食变异性的贝特类组合物。 组合物的贝特类颗粒具有小于约2000nm的有效平均粒度。
-
公开(公告)号：US20100329976A1
公开(公告)日：2010-12-30
申请号：US12870749
申请日：2010-08-27
Applicant: Elaine Merisko-Liversidge , H. William Bosch , Greta G. Cary , John Pruitt , Tuula Ryde , Rajeev Jain , Amy Walters
Inventor： Elaine Merisko-Liversidge , H. William Bosch , Greta G. Cary , John Pruitt , Tuula Ryde , Rajeev Jain , Amy Walters
IPC: A61K31/565 , A61K9/00 , A61K9/20 , A61K9/48 , A61K38/16 , A61K31/7052 , A61K49/00 , A61K36/00 , A61K36/886 , A61K36/82 , A61K36/55 , A61K35/60 , A61K35/00 , A61K39/00 , A61P9/00 , A61P35/00
CPC classification number: A61K31/00 , A61K9/145 , A61K9/146 , A61K9/148 , A61K31/565
Abstract: Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.
Abstract translation: 描述包含至少一种难溶性血管发生抑制剂和至少一种表面稳定剂的纳米颗粒组合物。 纳米颗粒组合物具有小于约2000nm的平均粒度。 本发明还描述了制备和使用这些组合物的方法。
-
公开(公告)号：US20100322852A1
公开(公告)日：2010-12-23
申请号：US12870722
申请日：2010-08-27
Applicant: Elaine Merisko-Liversidge , H. William Bosch , Greta G. Cary , John Pruitt , Tuula Ryde , Rajeev Jain , Amy Walters
Inventor： Elaine Merisko-Liversidge , H. William Bosch , Greta G. Cary , John Pruitt , Tuula Ryde , Rajeev Jain , Amy Walters
IPC: A61K31/565 , A61K9/00 , A61K38/16 , A61K31/7052 , A61K49/00 , A61K36/00 , A61K36/886 , A61K36/82 , A61K36/55 , A61K35/60 , A61K35/00 , A61K39/00 , A61P9/00 , A61P35/00
CPC classification number: A61K31/00 , A61K9/145 , A61K9/146 , A61K9/148 , A61K31/565
Abstract: Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.
-
公开(公告)号：US20080220075A1
公开(公告)日：2008-09-11
申请号：US12076247
申请日：2008-03-14
Applicant: Elaine Merisko-Liversidge , H. William Bosch , Greta G. Cary , John Pruitt , Tuula Ryde , Rajeev Jain , Amy Walters
Inventor： Elaine Merisko-Liversidge , H. William Bosch , Greta G. Cary , John Pruitt , Tuula Ryde , Rajeev Jain , Amy Walters
CPC classification number: A61K31/565 , A61K9/145 , A61K9/146 , A61K31/00
Abstract: Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.
Abstract translation: 描述包含至少一种难溶性血管发生抑制剂和至少一种表面稳定剂的纳米颗粒组合物。 纳米颗粒组合物具有小于约2000nm的平均粒度。 本发明还描述了制备和使用这些组合物的方法。
-
Patent Agency Ranking
公开(公告)号：US20080050461A1
公开(公告)日：2008-02-28
申请号：US11928250
申请日：2007-10-30
Applicant: Elaine Merisko-Liversidge , H. William Bosch , Greta Cary , John Pruitt , Tuula Ryde , Rajeev Jain , Amy Walters
Inventor： Elaine Merisko-Liversidge , H. William Bosch , Greta Cary , John Pruitt , Tuula Ryde , Rajeev Jain , Amy Walters
IPC: A61K31/565 , A61K36/00 , A61K38/02 , A61K9/14
CPC classification number: A61K31/00 , A61K9/145 , A61K9/146 , A61K9/148 , A61K31/565
Abstract: Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.
-
公开(公告)号：US07320802B2
公开(公告)日：2008-01-22
申请号：US10692855
申请日：2003-10-27
Applicant: Tuula Ryde , Evan E. Gustow , Stephen B. Ruddy , Rajeev Jain , Rakesh Patel , Michael John Wilkins
Inventor： Tuula Ryde , Evan E. Gustow , Stephen B. Ruddy , Rajeev Jain , Rakesh Patel , Michael John Wilkins
CPC classification number: A61K31/19 , A61K9/145 , A61K9/146 , A61K9/2077 , A61K31/14 , A61K31/216 , A61K45/06 , Y10T428/29 , A61K2300/00
Abstract: The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.
Abstract translation: 本发明涉及具有改善的药代动力学特征和降低的进食/禁食变异性的贝特类组合物。 组合物的贝特类颗粒具有小于约2000nm的有效平均粒度。
-
8.发明授权公开(公告)号：US07198795B2
公开(公告)日：2007-04-03
申请号：US10323736
申请日：2002-12-20
Applicant: Eugene R. Cooper , John A. Bullock , John R. Chippari , John L. Schaefer , Rakesh A. Patel , Rajeev Jain , Joost Strasters , Niels P. Ryde , Stephen B. Ruddy
Inventor： Eugene R. Cooper , John A. Bullock , John R. Chippari , John L. Schaefer , Rakesh A. Patel , Rajeev Jain , Joost Strasters , Niels P. Ryde , Stephen B. Ruddy
CPC classification number: A61K9/1635 , A61K9/0095 , A61K9/145 , A61K9/146 , A61K9/1623
Abstract: Disclosed are in vitro methods for evaluating the in vivo redispersibility of dosage forms of poorly water-soluble active agents. The methods utilize media representative of in vivo human physiological conditions.
Abstract translation: 公开了用于评价水溶性差的活性剂的剂型的体内再分散性的体外方法。 该方法利用代表体内人体生理条件的介质。
-
9.发明授权公开(公告)号：US08309136B2
公开(公告)日：2012-11-13
申请号：US12729018
申请日：2010-03-22
Applicant: Eugene R. Cooper , John A. Bullock , John R. Chippari , John L. Schaefer , Rakesh A. Patel , Rajeev Jain , Joost Strasters , Niels P. Ryde , Stephen B. Ruddy
Inventor： Eugene R. Cooper , John A. Bullock , John R. Chippari , John L. Schaefer , Rakesh A. Patel , Rajeev Jain , Joost Strasters , Niels P. Ryde , Stephen B. Ruddy
CPC classification number: A61K9/1635 , A61K9/0095 , A61K9/145 , A61K9/146 , A61K9/1623
Abstract: Disclosed are in vitro methods for evaluating the in vivo redispersibility of dosage forms of poorly water-soluble active agents. The methods utilize media representative of in vivo human physiological conditions.
Abstract translation: 公开了用于评价水溶性差的活性剂的剂型的体内再分散性的体外方法。 该方法利用代表体内人体生理条件的介质。
-
公开(公告)号：US20100322853A1
公开(公告)日：2010-12-23
申请号：US12870745
申请日：2010-08-27
Applicant: Elaine Merisko-Liversidge , H. William Bosch , Greta G. Cary , John Pruitt , Tuula Ryde , Rajeev Jain , Amy Walters
Inventor： Elaine Merisko-Liversidge , H. William Bosch , Greta G. Cary , John Pruitt , Tuula Ryde , Rajeev Jain , Amy Walters
IPC: A61K31/565 , A61K9/00 , A61K9/20 , A61K9/48 , A61K38/16 , A61K31/7052 , A61K49/00 , A61K36/00 , A61K36/886 , A61K36/82 , A61K36/55 , A61K35/60 , A61K35/00 , A61K39/00 , A61P35/00 , A61P9/00 , A61P3/04
CPC classification number: A61K31/00 , A61K9/145 , A61K9/146 , A61K9/148 , A61K31/565
Abstract: Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.
-
-
-
-
-
-
-
-
-
Search Results
38
records
(took 0.028 seconds)
